European Immunology

Tumor Immunology & Personalized Cancer Immunotherapies

Tumor immunology is uncovering how cancer cells evade immune detection and how targeted immunotherapies can restore anti-tumor responses. Insights into tumor microenvironment biology, immune checkpoints, neoantigen presentation and cellular exhaustion are shaping the development of next-generation therapies. Personalized cancer immunotherapy integrates genomic sequencing, neoantigen prediction and tailored immune engineering to create patient-specific interventions. CAR-T cells, TCR-modified lymphocytes, tumor-infiltrating lymphocyte expansion, checkpoint inhibitors and oncolytic viruses represent core therapeutic tools. Strategies now focus on overcoming resistance, enhancing infiltration and reprogramming immunosuppressive microenvironments to support long-term remission. Combination therapies involving vaccines, cytokine engineering and metabolic modulation are showing promising results. Computational modeling and AI-driven immunotherapy design are accelerating individualized treatment planning. This evolving field continues to lead innovation in immune-based oncology.